News Roundup: Camber Energy, Inc. (NYSE:CEI), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)


Camber Energy, Inc. (NYSE:CEI)

Camber Energy, Inc. (NYSE:CEI) represented a move of 1.14 percent or $0 per share and closed its previous day trading session at $0.17. 7.74 Million Shares were traded in the last trading session with an Average Volume of 10.16 Million Shares. The stock currently has a Market Capitalization of 21.05 Million.

Camber Energy, Inc. is engaged in exploration of crude oil and natural gas. The company is primarily focusing on the development of Eagle Ford and Austin Chalk in Texas. Camber Energy, Inc., formerly known as Lucas Energy, Inc., is based in Houston, Texas.

The stock traded between $0.150 and $5.380 over 1-Year time period showing its price to sales ratio of 3.51. Camber Energy, Inc. (NYSE:CEI) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-25.44 and 200-Day Simple Moving Average of $-69.77. Its Price to Free Cash Flow is 0 and Price to Book of 2.8.

Analyst’s recommended the stock as 4 where 1 represents Strong Buy and 5 represents Sell.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

In the last trading session, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) added its value by -2.33% closing at the price of $3.36. The stock currently has market capitalization of 238.53 Million, with average volume of 3.81 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is showing beta of 1.94. This particular value of beta suggests that AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has historically moved 194% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is at $-0.16.

The stock currently has RSI of 46.34. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) topped its 52-week high price of $5.05 on 11/02/18 and 52-Week Low Price of $1.65 on 03/07/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.16% and monthly volatility of 10.57% respectively.